Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Localized disease treated with surgery only~ * pT2, pT3, or pT4~ * pN0 or pNx~ * No clinical signs of progressive disease~* Prostate-specific antigen (PSA) meeting the following criteria:~  * PSA ≤ 0.1 ng/mL after prostatectomy~ * PSA ≥ 0.2 ng/mL and \< 2 ng/mL at study entry~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 10 years~* No other cancer in the past 5 years except for treated basal cell skin cancer~* No known pituitary gland adenoma~* No uncontrolled hypertension (i.e., blood pressure ≥ 160 mm Hg systolic and/or 90 mm Hg diastolic)~* No geographical, social, or psychological condition that would preclude study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior hormonal therapy~* No prior pelvic radiotherapy~* No prior surgical or chemical castration~* At least 6 months since surgery for biological recurrence~* No other concurrent anticancer therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: ACTIVE_COMPARATOR): Exclusive Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) in treating patients who have undergone surgery for recurent or refractory Prostate Cancer
- II (Type: EXPERIMENTAL): Radiation Therapy 66 Gy (prostatic bed) / 46 Gy (Pelvis with lymph nod involvement) and GOSERELIN ACETATE in treating patients who have undergone surgery for recurent or refractory Prostate Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).